“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in -
Last close As at 09/06/2023
-0.02
▲ 0.01 (100.00%)
Market capitalisation
—
Edison Investment Research is terminating coverage on MagForce. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Forecast net debt (€m)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (73.9) | (99.0) | (99.5) |
| Relative | (75.2) | (99.0) | (99.4) |
| 52 week high/low | €3.6/€0.0 |
MagForce is a German med-tech firm with a CE-mark approved nanotechnology cancer treatment. This consists of NanoTherm (iron nanoparticles), Nanoplan (software) and NanoActivator (a device that produces a powerful magnetic field to heat the nanoparticles, which destroys or sensitises tumour cells to therapy).
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.6 | 19.3 | (9.7) | (0.35) | N/A | N/A |
| 2021A | 0.4 | (6.1) | (8.9) | (0.30) | N/A | N/A |
| 2022E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
